Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

LPCN

Lipocine (LPCN)

Lipocine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateTimeSourceHeadlineSymbolCompany
10/06/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
10/06/202422:00PR Newswire (US)Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/06/202407:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
08/06/202407:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/06/202406:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
04/06/202407:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
04/06/202407:09Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LPCNLipocine Inc
09/05/202422:00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
09/05/202420:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
09/05/202420:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/05/202422:00PR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
08/05/202420:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/05/202422:00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202421:00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202423:00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202423:00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
08/03/202409:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
08/03/202400:00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202422:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202422:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
07/03/202400:00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/03/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
13/02/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/02/202400:00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
03/02/202400:00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
19/01/202400:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
19/01/202400:00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN